Search Results for “brca” - Page 10 - Ovarian Cancer Research Alliance

Feb 23, 2021

What Are Biomarkers?

...with ovarian cancer, a doctor may test for predictive biomarkers, such as BRCA and other cancer-causing gene mutations. Detected through blood or saliva tests, these mutations can signal to a...

Jun 6, 2014

2014 ASCO Research Round-Up

...are known to be highly effective in BRCA positive women. Yet, especially striking are the results in women who do not have a BRCA mutation – they had an increase...

Jun 17, 2014

Report from the 2014 American Society of Clinical Oncology Annual Meeting

...olaparib. BRCA positive patients had only a slight increase in PFS (19.4 vs. 16.5 months), which is to be expected since PARP inhibitors are known to be highly effective in BRCA positive women. Yet,...

Jan 2, 2013

Partner Member Profile: Bright Pink

Lindsay Avner founded Bright Pink in 2007, shortly after she learned that she carried a mutation in the BRCA gene. Just 22 years old when she was tested, Lindsay realized...

What is CA-125? Understanding the Blood Test

Learn what CA-125 is, how this ovarian cancer biomarker is used, and why it’s not a screening tool. Explore its role in diagnosis, monitoring, and recurrence.

Detection & Diagnosis

Explore the role of imaging exams, the CA-125 blood test, and surgical biopsy in detecting ovarian cancer. Learn about key steps to take in your health journey.

Apr 21, 2017

OCRFA Research Finds New Genetic Variants Linked to Ovarian Cancer

A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2...

Nov 12, 2020

What’s New in Ovarian Cancer Research and Treatment

...for ovarian cancer continues to show promise. The SOLO-1 trial, for instance, illustrates that the PARP inhibitor olaparib can significantly improve progression-free survival for patients with an inherited BRCA mutation....

Dec 22, 2014

FDA Approves Olaparib for Ovarian Cancer

(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly...

Dec 11, 2017

The Relationship Between Cytotoxic CD8 Tumor-Infiltrating Lymphocytes and Overall Survival in High Grade Serous Ovarian Cancer

...TILs, as well as BRCA 1 mutation carriers. BRCA 2 carriers were not observed to benefit from them. The study authors concluded, “that the extent of infiltration is prognostic, not...

Need to talk?

Free Genetic Testing Program

Global Ovarian Cancer Research Consortium Awards Inaugural AI Accelerator Grant

Announcing OCRA's New Center for Public Policy

Become a Monthly Donor

OCRA Collaborates with OPERATION WIPE OUT

Suggested Links

Quick Links

Search Results for: "brca"

Search Again